Latest Breaking News On - Committee for medicinal products - Page 17 : comparemela.com

LEO Pharma LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021 Monday, April 26, 2021 1:00PM IST (7:30AM GMT)   Ballerup, Denmark & Madison, N.J., United States:    Interim analysis at 56 weeks from ECZTEND, an open-label extension trial, demonstrates sustainable and durable efficacy of tralokinumab in adult patients 1 Patients enrolled in ECZTRA 1 and 2 parent trials who continued into ECZTEND have now been treated with tralokinumab for two years 1 1 ​ LEO Pharma A/S, a global leader in medical dermatology, today announced results on the long-term safety and efficacy profile of tralokinumab in adult patients with moderate-to-severe atopic dermatitis. Results were shared as an oral presentation during the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021.

United statesLinda mayerAndrew blauveltOregon medical research centerGlobal researchEuropean medicines agency onAmerican academy of dermatology virtual meeting experienceNational library of medicineCommittee for medicinal products human useGlobal product communicationsAmerican academyDermatology virtual meeting experienceInvestigator global assessmentEczema areaSeverity indexExecutive vice president